CAUSALENS
24.1.2023 09:47:41 CET | Business Wire | Press release
causaLens, the London deep tech company and pioneer of Causal AI, today announced the launch of decisionOS, the first operating system using cause-and-effect reasoning for all aspects of an enterprise’s decision-making.
Causal AI is the technology that identifies the underlying web of causes, to provide critical decision-making insights that current machine learning fails to deliver. The technology is gaining momentum rapidly, with ‘big tech’ companies such as Microsoft, Amazon, Google, Meta, Spotify, Netflix and Uber who are investing heavily in the development of Causal AI, and it was recently featured in various Gartner hype cycles.
decisionOS optimises business decisions by embedding Causal AI models into decision workflows at any level of an organisation. Now enterprise users in all industry sectors will be able to go beyond relying on past patterns and correlations to make predictions, instead understanding cause and effect relationships to generate actionable insights that factor in business objectives and resource constraints. For example, retailers can use the recommendations and insights provided by decisionOS to decide on the best pricing for individual products, across specific locations, while considering the prevailing business environment.
Serving as a unique one-stop system, decisionOS can integrate all an enterprise’s decision workflows, such as product pricing and promotion; customer acquisition, retention and marketing spend optimization; optimising manufacturing processes; supply chain risk management, demand forecasting as well as inventory and order management; among many others.
Darko Matovski, causaLens CEO, said:
“All decisions in the enterprise require a causal understanding. The best decisions are made when domain experts’ knowledge is combined with AI that truly understands cause-and-effect, and reasons like humans do. decisionOS makes it possible to evaluate different scenarios and design optimal actions for your business while providing full transparency of the decision-making process."
decisionOS enables data scientists to build powerful Causal AI models and use its application building framework to create customised full stack decision-making applications for business stakeholders. decisionOS also provides capabilities to operationalize decision workflows and integrate with other enterprise systems.
Takashi Hiramatsu, Senior Manager, Murata said:
“Understanding the causal drivers behind demand is critical. decisionOS enhances our supply chain visibility and enhances our domain experts’ ability to run powerful what-if analyses.”
decisionOS will be presented, including a demo, on 16th February 4pm GMT.
Sign up!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Surging, but Businesses Are Struggling to Prove the Value, HTEC Global Study Finds15.10.2026 10:42:00 CEST | Press release
Research among 1,500 C-suite executives finds 77% believe people and processes now constrain AI value more than technology HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015407055/en/ HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. The independent study finds that 79% of organizations have increased AI investment over the past ye
Too Good To Go Expands Its Marketplace Beyond Food15.10.2026 09:30:00 CEST | Press release
Too Good To Go, the world's largest marketplace for surplus food, today announced that it is expanding its Marketplace beyond food, enabling retailers to redistribute surplus across personal care — including skincare, haircare, oral care and beauty products — pet care, flowers and plants, nutrition and supplements, and home, initially spanning cleaning and laundry products and décor. More than 8,500 stores already supply products across these areas, around one third of which were already working with Too Good To Go to redistribute surplus food. “In today’s society, we have built incredibly efficient processes for producing and selling things at scale, creating abundance, but we have not built the same efficiency into making sure what is left over gets used. As our lives have become more convenient, we have become less conscious of what those things are worth. We used to finish what was on the plate, find a use for what we had and instinctively pause before throwing something away. Too
Flowdesk Europe Receives Payment Institution Authorization from the ACPR Under PSD215.10.2026 09:30:00 CEST | Press release
The authorization allows Flowdesk Europe to provide custody and transfer services for fiat-denominated stablecoins, complementing its MiCA CASP authorization and regulated offering for European clients. Flowdesk, a global liquidity provider and digital asset trading and infrastructure provider, today announced that its European entity, Flowdesk Europe, has been authorized as a Payment Institution by the French Prudential Supervision and Resolution Authority, l'Autorité de contrôle prudentiel et de résolution (ACPR), under the second Payment Services Directive (PSD2). The authorization allows Flowdesk Europe to provide custody and transfer services for e-money tokens (EMTs), the fiat-referenced stablecoins regulated under the Markets in Crypto-Assets (MiCA) regulation, to its clients across the European Union. The authorization follows the entity’s Crypto-Asset Service Provider (CASP) authorization received from the Autorité des Marchés Financiers (AMF) under MiCA at the end of June thi
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
